Mergers & acquisitions
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
Sinocare of Changsha may bid as much as $4B to acquire J&J’s diabetes medical device subsidiaries
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers.
Immune Design is a clinical-stage immunotherapy company.
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Analysts feel the company’s profit potential is starting to improve following a year in which its shares fell by more than 21%.
Investors and analysts have given it some thought and mostly think it’s a sensible acquisition.
PRESS RELEASES